Magazine Article | September 1, 2020

Eyes On Horizon, Buying Into Bio

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Horizon Therapeutics is one fiscally aware company that has put its money to work. Its original model was specialty pharma, which meant acquiring commercial drugs and remarketing them, usually in improved form. Now it is part of a trend of specialty pharma and other commercial companies entering the heart of the biopharma sector.

Revenues from its marketed products are fueling an integrated company with R&D focusing more on bio-based medicines such as monoclonal antibodies and genetically engineered proteins. Tim Walbert, its founding chairman, president, and CEO, has witnessed and directed the company’s transformation.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: